TransMedics Group, Inc. $TMDX Shares Bought by Capital Fund Management S.A.

Key Points

• Capital Fund Management S.A. increased its holdings in TransMedics Group by 100.4%, acquiring an additional 126,414 shares, bringing its total ownership to 252,294 shares valued at approximately $16.97 million.
• Multiple institutional investors significantly increased their positions in TransMedics Group during the fourth quarter, with Dimensional Fund Advisors LP raising its stake by 1,565.5%.
• Analysts have expressed positive sentiment towards TransMedics Group, with several raising their price targets; Morgan Stanley set its target at $123.00 while Canaccord Genuity Group increased theirs to $142.00.

Capital Fund Management S.A. increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 100.4% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 252,294 shares of the company's stock after buying an additional 126,414 shares during the period. Capital Fund Management S.A. owned 0.75% of TransMedics Group worth $16,974,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the stock. Credit Agricole S A grew its position in TransMedics Group by 116.0% during the 1st quarter. Credit Agricole S A now owns 24,079 shares of the company's stock valued at $1,620,000 after purchasing an additional 12,929 shares during the last quarter. Northern Trust Corp raised its stake in shares of TransMedics Group by 2.1% in the first quarter. Northern Trust Corp now owns 361,963 shares of the company's stock worth $24,353,000 after purchasing an additional 7,341 shares during the last quarter. Versor Investments LP bought a new position in shares of TransMedics Group during the first quarter valued at $503,000. Algert Global LLC boosted its position in shares of TransMedics Group by 8.9% during the first quarter. Algert Global LLC now owns 13,674 shares of the company's stock valued at $920,000 after buying an additional 1,120 shares during the last quarter. Finally, Raymond James Financial Inc. raised its position in TransMedics Group by 135.8% in the 1st quarter. Raymond James Financial Inc. now owns 145,393 shares of the company's stock worth $9,782,000 after buying an additional 83,722 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Price Performance

Shares of NASDAQ TMDX traded up $1.04 during mid-day trading on Friday, hitting $119.85. 1,032,110 shares of the company's stock traded hands, compared to its average volume of 1,241,494. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The company's 50-day moving average is $121.65 and its two-hundred day moving average is $101.51. The company has a market capitalization of $4.09 billion, a P/E ratio of 62.10 and a beta of 2.09.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm's revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity

In related news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider directly owned 13,955 shares of the company's stock, valued at $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward M. Basile sold 5,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the sale, the director directly owned 2,866 shares in the company, valued at approximately $362,405.70. The trade was a 63.56% decrease in their position. The disclosure for this sale can be found here. Insiders own 7.00% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TMDX. Oppenheimer increased their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Canaccord Genuity Group upped their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Piper Sandler reissued an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Wall Street Zen upgraded TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $123.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.